메뉴 건너뛰기




Volumn 52, Issue 3, 2003, Pages 319-323

Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects

Author keywords

Amprenavir; Genotype; HIV; Lopinavir; Resistance

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

EID: 0141518171     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg392     Document Type: Article
Times cited : (8)

References (32)
  • 1
    • 0029092503 scopus 로고
    • In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
    • Partaledis, J. A., Yamaguchi, K., Tisdale, M. et al. (1995). In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. Journal of Virology 69, 5228-35.
    • (1995) Journal of Virology , vol.69 , pp. 5228-5235
    • Partaledis, J.A.1    Yamaguchi, K.2    Tisdale, M.3
  • 2
    • 0029133978 scopus 로고
    • Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
    • Tisdale, M., Myers, R. E., Maschera, B. et al. (1995). Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy 39, 1704-10.
    • (1995) Antimicrobial Agents and Chemotherapy , vol.39 , pp. 1704-1710
    • Tisdale, M.1    Myers, R.E.2    Maschera, B.3
  • 3
    • 0036174439 scopus 로고    scopus 로고
    • Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: Selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors
    • Maguire, M., Shortino, D., Klein, K. et al. (2002). Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrobial Agents and Chemotherapy 46, 731-8.
    • (2002) Antimicrobial Agents and Chemotherapy , vol.46 , pp. 731-738
    • Maguire, M.1    Shortino, D.2    Klein, K.3
  • 4
    • 0038369071 scopus 로고    scopus 로고
    • HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study
    • Ait-Khaled, M., Rakik, A., Griffin, P. et al. (2003). HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antiviral Therapy 8, 111-20.
    • (2003) Antiviral Therapy , vol.8 , pp. 111-120
    • Ait-Khaled, M.1    Rakik, A.2    Griffin, P.3
  • 5
    • 4243521639 scopus 로고    scopus 로고
    • Impact on fitness conferred by amprenavir resistance mutations
    • In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1766, American Society for Microbiology, Washington, DC, USA
    • Harris, W., Randall, S., Manohitharajah, V. et al. (2001). Impact on fitness conferred by amprenavir resistance mutations. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1766, p. 338. American Society for Microbiology, Washington, DC, USA.
    • (2001) , pp. 338
    • Harris, W.1    Randall, S.2    Manohitharajah, V.3
  • 6
    • 0037012979 scopus 로고    scopus 로고
    • Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
    • Prado, J. G., Wrin, T., Beauchaine, J. et al. (2002). Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16, 1009-17.
    • (2002) AIDS , vol.16 , pp. 1009-1017
    • Prado, J.G.1    Wrin, T.2    Beauchaine, J.3
  • 7
    • 24444466690 scopus 로고    scopus 로고
    • Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance
    • In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 465, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Elston, R., Randall, S., Myers, R. et al. (2001). Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance. In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 465, p. 182. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2001) , pp. 182
    • Elston, R.1    Randall, S.2    Myers, R.3
  • 8
    • 0038360368 scopus 로고    scopus 로고
    • GW433908 in ART naive patients: Absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen
    • In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 598, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • MacManus, S., Yates, P., White, S. et al. (2003). GW433908 in ART naive patients: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 598, p. 271. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2003) , pp. 271
    • MacManus, S.1    Yates, P.2    White, S.3
  • 9
    • 0031849665 scopus 로고    scopus 로고
    • In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
    • Carrillo, A., Stewart, K. D., Sham, H. L. et al. (1998). In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Journal of Virology 72, 7532-41.
    • (1998) Journal of Virology , vol.72 , pp. 7532-7541
    • Carrillo, A.1    Stewart, K.D.2    Sham, H.L.3
  • 10
    • 0141661555 scopus 로고    scopus 로고
    • Multiple pathways to resistance to ABT-378 observed by in vitro selection
    • In Program and Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 1999. Abstract 117, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Mo, H., Chernyavskiy, T., Lu, L. et al. (1999). Multiple pathways to resistance to ABT-378 observed by in vitro selection. In Program and Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 1999. Abstract 117, p. 89. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (1999) , pp. 89
    • Mo, H.1    Chernyavskiy, T.2    Lu, L.3
  • 11
    • 0141550180 scopus 로고    scopus 로고
    • Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378
    • In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 452, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Brun, S., Kempf, D., Isaacson, J. et al. (2001). Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378. In Program and Abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001. Abstract 452, p. 178. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2001) , pp. 178
    • Brun, S.1    Kempf, D.2    Isaacson, J.3
  • 12
    • 0141773489 scopus 로고    scopus 로고
    • Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir or nelfinavir as initial therapy
    • In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 600, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Kempf, D., King, M., Moseley, J. et al. (2003). Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir or nelfinavir as initial therapy. In Program and Abstracts of the Tenth Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2003. Abstract 600, p. 272. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2003) , pp. 272
    • Kempf, D.1    King, M.2    Moseley, J.3
  • 13
    • 0038543353 scopus 로고    scopus 로고
    • Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples
    • Schnell, T., Schmidt, B., Moschik, G. et al. (2003). Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir and atazanavir in a panel of clinical samples. AIDS 17, 1258.
    • (2003) AIDS , vol.17 , pp. 1258
    • Schnell, T.1    Schmidt, B.2    Moschik, G.3
  • 14
    • 0033743891 scopus 로고    scopus 로고
    • Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors
    • Schmidt, B., Korn, K., Moschik, B. et al. (2000). Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrobial Agents and Chemotherapy 44, 3213-6.
    • (2000) Antimicrobial Agents and Chemotherapy , vol.44 , pp. 3213-3216
    • Schmidt, B.1    Korn, K.2    Moschik, B.3
  • 15
    • 0032750954 scopus 로고    scopus 로고
    • Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
    • Race, E., Dam, E., Obry, V. et al. (1999). Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 13, 2061-8.
    • (1999) AIDS , vol.13 , pp. 2061-2068
    • Race, E.1    Dam, E.2    Obry, V.3
  • 16
    • 0036387141 scopus 로고    scopus 로고
    • Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia
    • Paulsen, D., Liao, Q., Fusco, G. et al. (2002). Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Research and Human Retroviruses 18, 1011-9.
    • (2002) AIDS Research and Human Retroviruses , vol.18 , pp. 1011-1019
    • Paulsen, D.1    Liao, Q.2    Fusco, G.3
  • 17
    • 0036720761 scopus 로고    scopus 로고
    • Human Immunodeficiency Virus Type I genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor experienced patients
    • Masquelier, B., Breilh, D., Neau, D. et al. (2002). Human Immunodeficiency Virus Type I genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor experienced patients. Antimicrobial Agents and Chemotherapy 46, 2926-32.
    • (2002) Antimicrobial Agents and Chemotherapy , vol.46 , pp. 2926-2932
    • Masquelier, B.1    Breilh, D.2    Neau, D.3
  • 18
    • 0002583843 scopus 로고    scopus 로고
    • Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir
    • Elston, R., Wolfram, J., Richards, N. et al. (2001). Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir. Antiviral Therapy 6, Suppl. 1, 53-5.
    • (2001) Antiviral Therapy , vol.6 , Issue.SUPPL. 1 , pp. 53-55
    • Elston, R.1    Wolfram, J.2    Richards, N.3
  • 19
    • 0007361104 scopus 로고    scopus 로고
    • Amprenavir genotype resistance profile in protease inhibitor multi-experienced patients
    • Yvon, A., Descamps, D., Delaguerre, C. et al. (1999). Amprenavir genotype resistance profile in protease inhibitor multi-experienced patients. Antiviral Therapy 4, Suppl. 1, 29.
    • (1999) Antiviral Therapy , vol.4 , Issue.SUPPL. 1 , pp. 29
    • Yvon, A.1    Descamps, D.2    Delaguerre, C.3
  • 20
    • 24444450666 scopus 로고    scopus 로고
    • Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors
    • In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1769, American Society for Microbiology, Washington, DC, USA
    • Harrigan, P. R., Van Den Eynde, C. & Larder, B. (2001). Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors. In Program and Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, 2001. Abstract I-1769, p. 338. American Society for Microbiology, Washington, DC, USA.
    • (2001) , pp. 338
    • Harrigan, P.R.1    Van Den Eynde, C.2    Larder, B.3
  • 21
    • 0034909925 scopus 로고    scopus 로고
    • Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
    • Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2001). Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 75, 7462-9.
    • (2001) Journal of Virology , vol.75 , pp. 7462-7469
    • Kempf, D.J.1    Isaacson, J.D.2    King, M.S.3
  • 22
    • 0036768328 scopus 로고    scopus 로고
    • Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-infected patients receiving lopinavir/ritonavir therapy
    • Kempf, D. J., Isaacson, J. D., King, M. S. et al. (2002). Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-infected patients receiving lopinavir/ritonavir therapy. Antiviral Therapy 7, 165-74.
    • (2002) Antiviral Therapy , vol.7 , pp. 165-174
    • Kempf, D.J.1    Isaacson, J.D.2    King, M.S.3
  • 23
    • 0141438655 scopus 로고    scopus 로고
    • Influence of genotypic resistance on the viral load response of 167 patients on lopinavir/r (LPV/r) including an analysis of new protease inhibitor resistant mutations in 21 patients who failed
    • In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 560-T, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Loutfy, M., Thompson, C., Trpeski, M. et al. (2002). Influence of genotypic resistance on the viral load response of 167 patients on lopinavir/r (LPV/r) including an analysis of new protease inhibitor resistant mutations in 21 patients who failed. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 560-T, p. 261. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2002) , pp. 261
    • Loutfy, M.1    Thompson, C.2    Trpeski, M.3
  • 24
    • 0008860323 scopus 로고    scopus 로고
    • Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy
    • Calvez, V., Cohen-Codar, I., Marcelin, A. G. et al. (2001). Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy. Antiviral Therapy 6, Suppl. 1, 64-5.
    • (2001) Antiviral Therapy , vol.6 , Issue.SUPPL. 1 , pp. 64-65
    • Calvez, V.1    Cohen-Codar, I.2    Marcelin, A.G.3
  • 25
    • 0003321265 scopus 로고    scopus 로고
    • Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients
    • In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 559-T, Foundation for Retrovirology and Human Health, Alexandria, VA, USA
    • Isaacson, J., Kempf, D., Calvez, V. et al. (2002). Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February, 2002. Abstract 559-T, p. 260. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
    • (2002) , pp. 260
    • Isaacson, J.1    Kempf, D.2    Calvez, V.3
  • 26
    • 0141438657 scopus 로고    scopus 로고
    • Genotypic predictors of response to lopinavir/ritonavir in clinical practice
    • Rice, H., Nadler, J., Schaenman, J. et al. (2003). Genotypic predictors of response to lopinavir/ritonavir in clinical practice. Antiviral Therapy 8, Suppl. 3, 169.
    • (2003) Antiviral Therapy , vol.8 , Issue.SUPPL. 3 , pp. 169
    • Rice, H.1    Nadler, J.2    Schaenman, J.3
  • 27
    • 0141773486 scopus 로고    scopus 로고
    • I84A and I84C mutations in protease confer high level resistance to protease inhibitors and impair replication capacity
    • Mo, H., Parkin, N., Stewart, K. D. et al. (2003). I84A and I84C mutations in protease confer high level resistance to protease inhibitors and impair replication capacity. Antiviral Therapy 8, Suppl. 3, 56.
    • (2003) Antiviral Therapy , vol.8 , Issue.SUPPL. 3 , pp. 56
    • Mo, H.1    Parkin, N.2    Stewart, K.D.3
  • 28
    • 0141550178 scopus 로고    scopus 로고
    • Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization
    • Kagan, R. M., Shenderovich, M., Ramnarayan, K. & Heseltine, P. N. R. (2003). Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. Antiviral Therapy 8, Suppl. 3, 54.
    • (2003) Antiviral Therapy , vol.8 , Issue.SUPPL. 3 , pp. 54
    • Kagan, R.M.1    Shenderovich, M.2    Ramnarayan, K.3    Heseltine, P.N.R.4
  • 29
    • 0000825264 scopus 로고    scopus 로고
    • A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response
    • Descamps, D., Masquelier, B., Mamet, J. P. et al. (2001). A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response. Antiviral Therapy 6, Suppl. 1, 103.
    • (2001) Antiviral Therapy , vol.6 , Issue.SUPPL. 1 , pp. 103
    • Descamps, D.1    Masquelier, B.2    Mamet, J.P.3
  • 30
    • 0037308542 scopus 로고    scopus 로고
    • Genotypic inhibitory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    • Marcelin, A. G., Lamotte, C., Delaugerre, C. et al. (2003). Genotypic inhibitory quotient as a predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrobial Agents and Chemotherapy 47, 594-600.
    • (2003) Antimicrobial Agents and Chemotherapy , vol.47 , pp. 594-600
    • Marcelin, A.G.1    Lamotte, C.2    Delaugerre, C.3
  • 31
    • 0038555736 scopus 로고    scopus 로고
    • Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance
    • Parkin, N. T., Chappey, C. & Petropoulos, C. J. (2003). Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17, 955-61.
    • (2003) AIDS , vol.17 , pp. 955-961
    • Parkin, N.T.1    Chappey, C.2    Petropoulos, C.J.3
  • 32
    • 0038238324 scopus 로고    scopus 로고
    • Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance
    • De Luca, A., Cingolani, A., Di Giambenedetto, S. et al. (2003). Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. Journal of Infectious Diseases 187, 1934-43.
    • (2003) Journal of Infectious Diseases , vol.187 , pp. 1934-1943
    • De Luca, A.1    Cingolani, A.2    Di Giambenedetto, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.